IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (Nasdaq:ELGX) today announced receipt of U.S. Food and Drug Administration (FDA) approval to manufacture the ePTFE graft material used in the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysm (AAA). More specifically, ePTFE is the graft material that covers the Powerlink System’s self-expanding cobalt chromium alloy stent cage. The Company’s self-manufactured ePTFE graft material meets the same product specifications as that currently in use in Powerlink System production.
